Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: MLN4924
DRUG: Fluconazole
DRUG: Itraconazole
DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Millennium Pharmaceuticals, Inc.